Rivaroxaban
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebrovascular Stroke
Conditions
Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases
Trial Timeline
Jan 18, 2019 → Dec 31, 2024
NCT ID
NCT03772457About Rivaroxaban
Rivaroxaban is a pre-clinical stage product being developed by Bayer for Cerebrovascular Stroke. The current trial status is unknown. This product is registered under clinical trial identifier NCT03772457. Target conditions include Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04416048 | Phase 2 | Terminated |
| NCT04096547 | Pre-clinical | UNKNOWN |
| NCT03772457 | Pre-clinical | UNKNOWN |
| NCT02387229 | Phase 3 | Terminated |
| NCT02116036 | Approved | Completed |
| NCT01464450 | Phase 1 | Completed |
| NCT01094886 | Phase 3 | Completed |
Competing Products
14 competing products in Cerebrovascular Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 23 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 85 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 30 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Atorvastatin 20mg | Brain Biotech | Approved | 77 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 25 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |